Analyst Update: athenahealth, Inc, Adeptus Health Inc, and Sarepta Therapeutics Inc

Analysts revised their ratings and price targets on athenahealth, Inc (ATHN), Adeptus Health Inc (ADPT), and Sarepta Therapeutics Inc (SRPT)

Jul 22, 2016 at 1:47 PM
facebook X logo linkedin


Analysts are weighing in on healthcare stocks athenahealth, Inc (NASDAQ:ATHN) and Adeptus Health Inc (NYSE:ADPT), as well as drugmaker Sarepta Therapeutics Inc (NASDAQ:SRPT)Here's a quick roundup of today's brokerage notes on ATHN, ADPT, and SRPT.

  • ATHN is getting crushed, after the company reported a suprise second-quarter loss. The brokerage crowd is only adding to the pain, with Deutsche Bank downgrading its opinion to "hold" from "buy," and joining two other analysts in slashing its price target. "Most concerning to us is that many of Athena's key underlying operating metrics are trending in the wrong direction," Deutsche Bank said with respect to athenahealth, Inc. At last check, the shares have plunged 11.7% at $121.14, and landed on the short-sale restricted list. In fact, ATHN isn't that far from its annual low of $114.59, touched in early February. Meanwhile, traders have been betting bearishly in the last two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). The stock's 10-day put/call volume ratio of 2.93 ranks near the top quartile of its annual range.
  • ADPT has sunk 5.3% at $46.64, on the heels of an earnings miss and negative round of analyst notes. Specifically, Jefferies, KeyBanc, and Goldman Sachs each lowered their price targets on the stock, which has now surrendered 14.5% year-to-date. Suffice it to say, Adeptus Health Inc call buyers could be feeling the heat. During the past 50 sessions at the ISE, CBOE, and PHLX, traders have bought to open 2.33 calls for each put -- a ratio that ranks in the bullishly skewed 89th percentile of its 52-week range.
  • SRPT is burning short sellers today, up 6.4% at $24.09 on a price-target hike to $26 from $20 at Needham. After all, nearly half of the stock's float is sold short, representing 6.2 times its average daily trading volume. On the charts, Sarepta Therapeutics Inc has been muscling its way higher since gapping sharply south in mid-January. That said, the shares have repeatedly been turned back in the $24-$25 area over the past several months, and now face another potential level of resistance at their overhead 320-day moving average.
Don't miss the market's next move! Sign up now for Schaeffer's Midday Market Check
 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI